Last Updated: May 11, 2026

Details for New Drug Application (NDA): 206966

✉ Email this page to a colleague

NDA 206966 describes XEGLYZE, which is a drug marketed by Hatchtech and is included in one NDA. There are two patents protecting this drug. Additional details are available on the XEGLYZE profile page.

The generic ingredient in XEGLYZE is abametapir. Additional details are available on the abametapir profile page.

Summary for 206966

Tradename:	XEGLYZE
Applicant:	Hatchtech
Ingredient:	abametapir
Patents:	2

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for 206966

Generic Entry Date for 206966^: ⤷ Start Trial* Constraining patent/regulatory exclusivity: ⤷ Start Trial Dosage: LOTION;TOPICAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Profile for product number 001

Active Rx/OTC/Discontinued:	DISCN	Dosage:	LOTION;TOPICAL			Strength	0.74%
Approval Date:	Jul 24, 2020	TE:		RLD:	Yes
Patent:	⤷ Start Trial	Patent Expiration:	Dec 17, 2034	Product Flag?	Y	Substance Flag?		Delist Request?
Patented Use:	TOPICAL TREATMENT OF HEAD LICE INFESTATION IN PATIENTS 6 MONTHS OF AGE AND OLDER
Patent:	⤷ Start Trial	Patent Expiration:	Oct 28, 2026	Product Flag?	Y	Substance Flag?		Delist Request?
Patented Use:	TOPICAL TREATMENT OF HEAD LICE INFESTATION IN PATIENTS 6 MONTHS OF AGE AND OLDER

Expired US Patents for NDA 206966

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Hatchtech	XEGLYZE	abametapir	LOTION;TOPICAL	206966-001	Jul 24, 2020	⤷ Start Trial	⤷ Start Trial
Hatchtech	XEGLYZE	abametapir	LOTION;TOPICAL	206966-001	Jul 24, 2020	⤷ Start Trial	⤷ Start Trial
Hatchtech	XEGLYZE	abametapir	LOTION;TOPICAL	206966-001	Jul 24, 2020	⤷ Start Trial	⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>Patent No.	>Patent Expiration

Complete Access Available with Subscription

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Summary for 206966

DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for 206966

Profile for product number 001

Make Better Decisions: Try a trial or see plans & pricing

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for 206966